What risks are associated with hormone therapy use in women?
An increase in stroke risk is associated with the use of hormone therapy in standard formulations of CEE/MPA as well as the use of SERMs. Additional studies are needed to draw conclusions about long-term hormone therapy use when initiated in perimenopausal women or postmenopausal women younger than 50 years of age. Prospective randomized trials of alternate forms of hormone therapy are ongoing.